Format
Sort by

Send to

Choose Destination

Search results

Items: 18

1.

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.

Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829.

PMID:
26260821
2.

Localized choroidal thickness variation and pigment epithelial detachment in dome-shaped macula with subretinal fluid.

Deobhakta A, Ross AH, Helal J Jr, Maia A, Freund KB.

Ophthalmic Surg Lasers Imaging Retina. 2015 Mar;46(3):391-2. doi: 10.3928/23258160-20150323-18.

PMID:
25835309
3.

Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid.

Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium.

JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878.

PMID:
25580725
4.

Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW; Tuberculosis Trials Consortium.

J Infect Dis. 2012 Oct 1;206(7):1030-40. Epub 2012 Jul 30.

5.

Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment.

Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium.

Int J Tuberc Lung Dis. 2012 Apr;16(4):473-9. doi: 10.5588/ijtld.11.0548.

PMID:
22325844
6.

Three months of rifapentine and isoniazid for latent tuberculosis infection.

Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team.

N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875.

7.

Syphilitic retinitis and panuveitis simulating acute retinal necrosis: case report.

Zambon F, Silva FL, Cavalcante AF, Nakashima Y, Helal J Jr.

Arq Bras Oftalmol. 2010 May-Jun;73(3):288-90.

8.

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; Tuberculosis Trials Consortium.

PLoS One. 2010 May 20;5(5):e10753. doi: 10.1371/journal.pone.0010753.

9.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30.

PMID:
19406981
10.

[Central vein occlusion in a patient using interferon and ribavirin: case report].

Helal J Jr, Zacharias LC, de Alencar LM.

Arq Bras Oftalmol. 2006 Jul-Aug;69(4):601-4. Portuguese.

11.

[Bilateral central retinal vein occlusion associated with blood hyperviscosity syndrome--case report].

Helal J Jr, Malerbi FK, Melaragno Filho R.

Arq Bras Oftalmol. 2005 Jan-Feb;68(1):126-8. Epub 2005 Mar 30. Portuguese.

12.

Biomechanical study of the final push-pull in archery.

Leroyer P, Van Hoecke J, Helal JN.

J Sports Sci. 1993 Feb;11(1):63-9.

PMID:
8450588
13.

The spatial integration effect of surface electrode detecting myoelectric signal.

Helal JN, Bouissou P.

IEEE Trans Biomed Eng. 1992 Nov;39(11):1161-7.

PMID:
1487279
14.

Surface myoelectric signals during ergocycle exrcises at various mechanical powers and pedalling rates.

Helal JN, Van Hoecke J, Garapon-Bar C, Goubel F.

J Electromyogr Kinesiol. 1992;2(4):242-51. doi: 10.1016/1050-6411(92)90027-G.

PMID:
20719617
15.

EMG spectral shift- and 31P-NMR-determined intracellular pH in fatigued human biceps brachii muscle.

BĂ©liveau L, Helal JN, Gaillard E, Van Hoecke J, Atlan G, Bouissou P.

Neurology. 1991 Dec;41(12):1998-2001.

PMID:
1745364
16.

A pseudoperiodic model for myoelectric signal during dynamic exercise.

Helal JN, Duchene J.

IEEE Trans Biomed Eng. 1989 Nov;36(11):1092-7.

PMID:
2807317
17.

The aerobic-anaerobic transition: re-examination of the threshold concept including an electromyographic approach.

Helal JN, Guezennec CY, Goubel F.

Eur J Appl Physiol Occup Physiol. 1987;56(6):643-9.

PMID:
3119335
18.

Timolol inhibition of aqueous humor production in the cat.

Helal J Jr, Macri FJ, Cevario SJ.

Gen Pharmacol. 1979;10(5):377-80. No abstract available.

PMID:
499738
Items per page

Supplemental Content

Loading ...
Write to the Help Desk